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Idiopathic nephrotic syndrome (INS) is a common 
chronic illness characterized by massive proteinuria 
and hypoalbuminemia in children.1 The 
International Study of Kidney Disease in Childhood 
reported that 84.5% of children with INS had 
minimal change nephrotic syndrome (MCNS) and 
the pathological hallmark of MCNS is the 
effacement of foot processes in glomeruli, revealed 
by ultrastructural analysis, without any 
inflammatory injury or immune complex 
deposition.2 Up to 90% of children with INS 
respond to steroid treatment. However, 60%–80% 
of the initially steroid-responsive patients relapse.3 
Dyslipidemia, an important pathophysiological 
change in INS,4 was postulated that it directly 
stimulates mesangial cells’ proliferation and 
secretion of inflammatory factors5 including IFN- 
which is a proinflammatory cytokine produced by 
T-cells and natural killer (NK) cells. There is some 
controversy with respect to the levels and role of 
IFN- in nephrotic syndrome.6 
MCNS was considered as an exclusive systemic 
disorder of T cells and cell-mediated immunity 4 
decades ago.7 A "two-hit" theory was proposed 
including the induction of CD80 (or B7-1) and Treg 
dysfunction, with or without impaired 
autoregulatory function of the podocytes.7 Recently, 
B-cell biology has been considered, since 
rituximab, a monoclonal antibody directed against 
CD20-bearing cells, showed good therapeutic 
potential in the treatment of both childhood and 
adulthood MCNS. However, the precise 
pathophysiology of MCNS still remains elusive.8  
It has been found that Tregs play a pivotal role 
in maintaining immune homeostasis and 
tolerogenecity.9 The Tregs dysregulation has been 
shown to cause imbalanced Th2/Th1 ratio with a 
predominant Th2 cytokine response and 
accordingly involved in the pathogenesis of many 
immune mediated diseases including MCNS 
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inducing a transient or persistent massive 
proteinuria, typically triggered by viral or bacterial 
infections, allergen- or T-cell-mediated release of 
cytokines (e.g., interleukin-13).10,11 
An association between various cytokines, 
circulatory factors and proteinuria have been shown 
to affect glomerular permeability,12 importantly, an 
increase in monocyte/macrophage cytokines, 
including interleukin IL1, IL12, IFN- and TNF-α, 
were shown to be responsible for initiation and 
recurrence of INS.13 
IFN- is secreted from T-helper cells, cytotoxic 
T cells, natural killer cells, and macrophages. 
Interferons are well recognized for their strong 
antiviral properties, their ability to regulate cell 
growth and their immunomodulatory effects.13  
IFN- promotes Th1 differentiation, eventually 
leading to cellular immunity and simultaneously 
inhibiting Th2 differentiation. It induces IL-12 
production from antigen presenting cells (APCs), 
such as dendritic cells and macrophages in addition 
to the release of the vascular permeability factors by 
peripheral blood monocytes (PBMCs) that are all 
responsible for induction of glomerular injury and 
heavy proteinuria in INS.12,14  
This study is aimed to evaluate the 
immunopathogenic role of IFN- in children with 
steroid sensitive idiopathic nephrotic syndrome 
(SSNS), through monitoring the changes in its 
levels with disease course.  
 
METHODS 
An observational follow up pilot study was 
conducted on newly diagnosed 25 pediatric SSNS 
patients, presenting to children’s Hospital, Ain-
Shams University, Cairo, Egypt, from June 2014 till 
the end of June 2016. An informed consent was 
obtained from each participant’s parents/caregivers 
after approval by the local Research Ethics 
Committee with approval number FMASU 1913/ 
2014.  
Patients enrolled in the study aged 2 to 8 years. 
They first presented with urinary protein/creatinine 
ratio > 2 g/mg, with hypoproteinemia and normal 
kidney function, before starting steroid therapy. 
Patients with secondary nephrotic syndrome, 
steroid resistant nephrotic syndrome or associated 
with systemic illness were excluded from the study. 
All patients received oral prednisolone at a dose of 
60 mg/m²/day.  
Children were followed up clinically for 28 days 
until full remission guided clinically and laboratory 
with normalization of serum albumin and 
disappearance of proteinuria according to KDIGO 
201215. Laboratory and clinical assessments were 
done at the time of diagnosis and at time of full 
remission and included serum total proteins and 
albumin, triglycerides (TG) and total cholesterol, 
complete blood count (CBC), complete urine 
analysis, protein creatinine ratio and serum level of 
IFN-γ by ELISA (the Quantikine Human IFN-γ 
Immunoassay, USA and Canada | R and D Systems, 
Inc. 614 McKinley Place NE, Minneapolis, MN 
55413, USA).  
 
Data Management and Statistical Analysis: 
The collected data was revised, coded, tabulated 
and introduced to a PC using Statistical package for 
Social Science (SPSS 13.0.1 for windows; SPSS 
Inc, Chicago, IL, 2001). Data were presented and 
suitable analysis was done according to the type of 
data obtained for each parameter. 
 
RESULTS 
The demographic and laboratory data are presented 
in table 1. There was improvement of serum 
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Table 1. Sociodemographic and laboratory parameters of the studied patients 
Variable Timing Mean ± SD Median (IQR) Range 
Age (years)  3.86 ± 1.68 3.1 (2.8 - 5.08) 2 - 7.5 
Weight (kg)  17.22 ± 4.84 15 (14.5 - 20) 11.5 - 30 
Systolic BP (mmHg)  95.84 ± 7.45 95 (90 - 100) 85 - 110 
Diastolic BP (mmHg)  63.8 ± 5.82 60 (60 - 70) 60 - 80 
S. IFN-γ (pg/ml) 
initial 27.12 ± 16.95 21 (16 - 30) 10 - 70  
at full remission 37.16 ± 14.03 35 (30 - 40) 20 - 80 
U. Prot./creat. ratio (g/mg) 
initial 7.77 ± 4.8 6.8 (3.6 - 11) 2.6 - 20 
at full remission 0.15±0.02 0.12 (0.08 – 0.16) 0.03 – 0.2 
S. albumin (g/dl) 
initial 1.4 ± 0.29 1.4 (1.1 - 1.5) 1 - 2.2 
at full remission 3.86 ± 0.6 3.8 (3.5 - 4.2) 2.5 - 5 
S. creatinine (mg/dl) 
initial 0.29 ± 0.12 0.2 (0.2 - 0.3) 0.2 - 0.6 
at full remission 0.26 ± 0.07 0.3 (0.2 - 0.3) 0.2 - 0.5 
Blood urea (mg/dl) 
initial 17.72 ± 7.62 17 (12 - 22) 7 - 37 
at full remission 19.92 ± 6.2 20 (16 - 22) 10 - 35 
TLC (*103/µl) 
initial 10.03 ± 2.62 9.5 (8 - 12.2) 5.4 - 14 
at full remission 13.27 ± 2.47 14 (11 - 15) 7.9 - 18 
Hemoglobin (gm/dl) 
initial 12.23 ± 1.15 12.4 (11.5 - 13) 10 - 15 
at full remission 12.73 ± 1.04 12.5 (12 - 13.6) 10.8 - 14.5 
Platelets (*103/µl) 
initial 393.64 ± 81.76 400 (350 - 453) 233 - 500 
at full remission 362 ± 95.25 350 (280 - 450) 230 - 552 
S. total cholesterol (mg/dl)  
initial 488 ±63.4 470 (331 – 527) 400-600 
at full remission 279 ±67.7 256 (214 – 357) 185-437 
S. triglycerides (mg/dl)  
initial 240.6 ±74 204.8 (160 - 297) 144-438 
at full remission 89.5 ±33 67 (55 – 94) 34-150 
IFN-γ: interferon gamma; BP: blood pressure; prot./creat. ratio: protein/creatinine ratio, TLC: total leucocytic count; S.: serum; U.: 
urinary; SD: standard deviation; IQR: interquartile range. 
 




Paired t test 
t p significance 
Initial 27.12 16.95 
3.35 0.003 S 
Remission 37.16 14.03 
IFN-γ: interferon gamma, SD: standard deviation, S: significant 
 
The serum level of IFN-γ showed significant increase at time of full remission with 88% of patients showing 
a rise in the levels from baseline. 
 
Table 3. The frequency and average percentage of change in serum IFN-γ from initial values.  
  N % 
Frequency of IFN-γ change  
Increased 22 88% 
Decreased 3 12% 
Average percentage of change  25 60.8% 
 






Age (years) -0.071 0.735 
U. Prot./creat. ratio (g/mg) 0.104 0.621 
Serum  albumin (g/dl) -0.297 0.149 
Total proteins (g/dl) -0.227 0.276 
S. triglyceride  (mg/dl) -0.036 0.864 
S. total cholesterol (mg/dl) 0.045 0.832 
Total  leucocytic count (103/µL) 0.202 0.333 
Absolute neutrophil  count (103/µL) 0.405 0.045 
Absolute lymphocytic count (103/µL)  0.372 0.067 
S.: serum; U.: urinary; IFN- γ: interferon gamma, prot./creat. ratio: protein creatinine ratio. 
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A moderate correlation was found between serum levels of IFN-γ and the absolute neutrophil count and a 
weak one with absolute lymphocytic count at initial diagnosis. Otherwise, there were no significant 
correlations.  
 





S. albumin (g/dl) -0.283 0.170 
Total  leucocytic count (103/µL) -0.042 0.843 
Absolute neutrophil  count (103/µL) 0.020 0.923 
Absolute lymphocytic count (103/µL)  0.095 0.651 
S. triglyceride  (mg/dL) -0.059 0.779 
S. total cholesterol (mg/dL) -0.140 0.504 
Cumulative dose of prednisolone  (mg) 0.4 0.21 
S.: serum; IFN-γ: interferon gamma. 
 
DISCUSSION 
In this study, serum levels of IFN-γ of the 
studied patients were noted to be non-significantly 
lower at diagnosis of nephrotic syndrome compared 
to remission. With disease remission, serum IFN-γ 
increased in most of the patients (22 out of 25) with 
percentage change ranging from 11% to 200% and 
only 3 had decreased levels, with percentage change 
ranging from -17% to -57%. The predominant rise 
in level suggests the recovery of some balance 
between Th1 and Th2 with subsequent 
normalization of Th1 cytokine profile including 
IFN-γ with consequent remission of NS. 
Concerning the 3 patients who showed a drop in 
IFN-γ at remission, their TLC was elevated at that 
time suggesting the occurrence of concomitant 
infection that might explain the initially high IFN-γ 
levels.  
Prior studies reported that the serum level of 
IFN-γ was significantly low at the diagnosis of 
nephrotic syndrome in comparison to their 
respective values at remission and controls, 
supporting a role for Tregs dysregulation with a 
predominant effect of T helper 2 (Th2) cells in the 
pathogenesis of INS and suppressed effect of T 
helper 1 (Th1) cells and its secreted 
cytokines.2,14,16,17,18 In contradiction to our finding, 
IFN-γ was found to be significantly higher in 
patients with active nephrotic syndrome at 
diagnosis, whereas remissions are characterized by 
downregulation of that cytokine. The authors 
related their finding to the different cells of origin 
of IFN-γ (dendritic cells, macrophages and other 
antigen presenting cells) other than Th1 cells which 
are not the master cells in the immunopathogenesis 
of nephrotic syndrome.6 Although the present study 
confirmed that IFN-γ had no significant correlation 
with urinary protein creatinine ratio at initial 
diagnosis, their study demonstrated that serum IFN-
γ correlated positively with 24-hour urinary 
proteins.6  
Serum IFN-γ in our study had negative, though 
insignificant correlations with serum triglycerides 
and total cholesterol at full remission, lending 
support for the absence of a role for IFN-γ in 
promoting the inflammation mediated by 
dyslipidemia in patients with INS  
Limitations of the study were absence of control 
group, small sample size being a pilot study, with a 
relatively short duration and narrow scale with 
exclusion of other types of INS (resistant and 
dependent).  
This study points to a role for the relatively 
lower serum IFN-γ at diagnosis than at remission, 
in the immunopathogenesis of INS and the rise in 
its serum level might be a marker of remission 
induction. Further studies on renal biopsy 
specimens are needed to determine the renal in situ 
effect of IFN-γ. 
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